Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Halozyme Therapeutics Inc Call to Discuss Plans to Focus Strategy on ENHANZE® Drug Delivery Technology Transcript

Nov 04, 2019 / 01:30PM GMT
Release Date Price: €6.08
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Halozyme update call.

(Operator Instructions)

Please be advised that today's conference is being recorded.

(Operator Instructions)

I'd now like to hand the conference over to your speaker today, Al Kildani, Vice President of Investor Relations and Corporate Communications. Please go ahead, sir.

Albert S. Kildani;Helen I. Torley
Halozyme Therapeutics, Inc. - VP of IR & Corporate Communications;Halozyme Therapeutics,

Good morning, and welcome to our call. Please refer to the 2 press releases issued by the company this morning for today's call. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer. Also on the call for the Q&A portion is Laurie Stelzer, our Chief Financial Officer.

During the call, we will be making forward-looking statements. I refer you to our SEC filings for a full listing of the risks and uncertainties.

I'll now turn the call over to Helen.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot